About: Liver Function in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Liver Function in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Liver Function in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-Analysis
Creator	Alizadeh-Navaei, Reza Heydari, Keyvan Zahedi, Mohammad Abounoori, Mahdi Ghazaeian, Monireh Malekan, Mohammad Mortazavi, Parham Nasirzadeh, Amirreza Sheydaee, Fateme Tajik, Fatemeh Yousefi, Mohammad
source	MedRxiv
abstract	Introduction:The outbreak of new coronavirus has become a global public health challenge. Given a consequential liver function, and the high risk of death coming from liver disorders, the assessment of Novel Coronavirus Disease on liver function is importance. Hence, we carried out this meta-analysis to heightening insight into the occult features of COVID 19, which is likely to affect liver function. Method:This study was performed using databases of Web of Science, Scopus, and PubMed. We considered English cross-sectional and case-series papers, which reported available findings on the association between liver injury and COVID-19 infection. We used the STATA v.11 and random effect model for data analysis. Result:In this present meta-analysis, 52 papers, including 8,463 COVID-19 patients, were studied. The prevalence of increased liver enzymes among the patients, including Alanine aminotransferase, Aspartate aminotransferase, were 30% and 21% in non-severe patients, respectively, which were 38% and 48% in severe patients. The prevalence of increasing C-reactive protein, Lactate dehydrogenase, D-dimer, and Bilirubin were 55%, 39%, 28%, and 10% in non-severe patients respectively, which were 78%, 75%, 79% and 17% in sever patients.The prevalence of liver toxicity as a complication of COVID-19 was 20%.Also patients who have severe condition are 5.54, 4.22, 4.96, 4.13 and 4.34 times more likely to have elevated CRP, ALT, AST, LDH, D-dimer enzymes retrospectively. Conclusion:Elevation of some liver markers were higher in patients with severe COVID-19 infection. All to gather, we assumed that abnormal liver markers could act as a prognostic factor for a better survey of COVID-19.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1101/2020.05.20.20108357
has license	medrxiv
sha1sum (hex)	1f111ba1f1a02e07c05fbf858501d3a0477df1cd
schema:url	https://doi.org/10.1101/2020.05.20.20108357
resource representing a document's title	Liver Function in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-Analysis
resource representing a document's body	covid:1f111ba1f1a02e07c05fbf858501d3a0477df1cd#body_text
is schema:about of	named entity 'liver' named entity 'Systematic' named entity 'NOVEL CORONAVIRUS' named entity 'DEATH' named entity 'CHALLENGE' named entity 'OUTBREAK' named entity 'consequential' named entity 'global public health' named entity 'meta-analysis' named entity 'occult' named entity 'risk of death' named entity 'liver function' named entity 'Liver Function' named entity 'Novel Coronavirus Disease' named entity 'liver function' named entity 'hepatic' named entity 'liver' named entity 'sample size' named entity 'SARS-CoV-2' named entity 'AST' named entity 'COVID19' named entity 'coagulopathy' named entity 'single-stranded' named entity 'liver function' named entity 'overconsumption' named entity 'AST' named entity 'liver' named entity 'infection' named entity 'total Bilirubin' named entity 'coronaviridae' named entity 'drug-induced' named entity 'AST' named entity 'receptor' named entity 'liver dysfunction' named entity 'albumin' named entity 'genetic sequence' named entity 'subgroup analysis' named entity 'hepatocyte' named entity 'liver injury' named entity 'sepsis' named entity 'Web of Science' named entity 'liver damage' named entity 'receptor' named entity 'coagulopathy' named entity 'TBIL' named entity 'Liver test' named entity 'COVID' named entity 'Intensive care unit' named entity 'Aspartate aminotransferase' named entity 'CoVID' named entity 'liver' named entity 'D-dimer' named entity 'LDH' named entity 'Liver function' named entity 'steroids' named entity 'C-reactive protein' named entity 'COVID' named entity 'AST' named entity 'kidney' named entity 'D-dimer' named entity 'drug-induced' named entity 'ESR' named entity 'AST' named entity 'Lopinavir/ritonavir' named entity 'infection' named entity 'SARS-CoV-2' named entity 'meta-analysis' named entity 'medical subject headings' named entity 'medRxiv' named entity 'Hydroxychloroquine' named entity 'COVID-19' named entity 'Albumin' named entity 'coronavirus disease' named entity 'asymptomatic' named entity 'liver cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software